Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Cancer Drug Zevalin May Finally Thrive Under Spectrum

This article was originally published in The Pink Sheet Daily

Executive Summary

The small oncology company may be able to succeed with the non-Hodgkin lymphoma drug where others have failed.
Advertisement

Related Content

Spectrum’s Zevalin Still Living In Rituxan’s Shadow, FDA Advertising Letter Shows
Radiotherapeutics Market Snapshot: This Sector Is Getting Hot
Spectrum Hopes For Synergies With Allos Acquisition Amid Phase III Setback
Zevalin Completes Transition To ASP-Based Reimbursement In OPPS
CTI Bags Cash, Turns Its Back On Zevalin
CTI Bags Cash, Turns Its Back On Zevalin

Topics

Advertisement
UsernamePublicRestriction

Register

PS071709

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel